The Relationship Between the Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio and Disease Activity in Patients with Psoriatic Arthritis

Background: The aim of this cross-sectional study was to analyze the monocyte-tohigh-density lipoprotein ratio (MHR) as an inflammatory marker in patients with psoriatic arthritis (PsA) and healthy controls (HCs), as well as to determine the association between MHR and PsA severity. Methods: This cross-sectional study included patients with PsA (n= 66) and age and sex-matched HCs (n= 68). Sociodemographic data and laboratory parameters were recorded in the study group. Disease Activity in PSoriatic Arthritis (DAPSA) was used to assess disease activity, while the Health Assessment Questionnaire (HAQ) was used for general health assessments. Disease Activity in PSoriatic Arthritis and HAQ were evaluated in the patient group. We compared sociodemographic, laboratory parameters, and the MHR between patients with PsA and HCs. Factors influencing MHR were assessed by regression analysis. Results: Patients with PsA revealed increased MHR compared to HCs (P= .025). In regression analysis, a DAPSA score of 15 or higher results in a 3.08 unit rise in the MHR, compared to a DAPSA score of 14 or below. In individuals with coronary artery disease (CAD), MHR increases by 7.56 units. Patients with moderate-severe PsA (DAPSA ≥ 15) had significantly elevated levels of C-reactive protein, erythrocyte sedimentation rate, and MHR compared to patients with remission-mild PsA (DAPSA ≤ 14) (P < .001, <.001, .026, respectively). Conclusions: Monocyte-to-high-density lipoprotein ratio can be used as an inflammatory marker in the follow-up of patients with PsA. Patients with PsA without evidence of active disease should also be evaluated for CAD in the presence of a high MHR value.